xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

315

ICAR SINONASAL TUMORS

TABLE XXVI.2 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Varelas et al. 1835

1. Most common primary sites were maxillary sinus and nasal cavity 2. OS was 70% at 2 years and 54% at 5 years 3. Chemotherapy and RT were associated with improved prognosis 1. Advanced age, higher Ann Arbor stage, and ENKTL histology associated with worse OSandDSS 2. RT associated with improved OS andDSS 1. Survival rates by lymphoma subtype were 56% for BCL 2. CRT resulted in significantly 1. OS was 82% at 12 months and 73% at 36 months 2. Prognosis depends on histologic type, Ann Arbor stage at diagnosis, and the therapeutic options 1. Survival is significantly improved for those treated with RT 2. Involvement of multiple sinuses is a negative prognostic factor 1. With a CHOP or CHOP-like chemotherapy regimen, 10 achieved CR and three PR 2. During 80-month follow-up, seven relapsed or progressed (four in the CNS) 3. Consider CNS prophylaxis in sinonasal lymphoma 1. OS for the entire group at 10 years was 78% 2. Combined-modality approach higher OS rates than chemotherapy alone

1273 cases of DLBCL of the sinonasal tract

1. Clinicodemo graphic factors 2. OS

2019 4

Retrospective database study (SEER)

Hanet al. 1840

2017 4

Retrospective database study (SEER)

1119 nasopharyngeal lymphoma cases (77.5% BCL)

1. OS 2. DSS

Steele et al. 1839

1. OS 2. Survival by treatment modality

2016 4

Retrospective case series

18 patients with sinonasal lymphoma

Lombard

2015 4

Retrospective case series

22 patients with non-Hodgkin

OS

et al. 1896

lymphoma of the sinonasal cavity

Kanamuri et al. 1765

852 cases of sinonasal DLBCL in SEER

1. DSS 2. Survival by treatment modality

2014 4

Retrospective database study (SEER)

Oprea et al. 1833

2005 4

Retrospective case series

14 consecutive DLBCL cases treated with CHOP

Complete or partial

remission (CR andPR)

Proulx et al. 1766

OS

2003 4

Retrospective case series

23 patients with extranodal non-Hodgkin’s

with locoregional RT and systemic chemotherapy is recommended

lymphoma of the paranasal sinuses

Quraishi

2001 4

Retrospective case series

24 patients with non-Hodgkin’s lymphoma of

OS

1. OS at 5 years was 40% 2. DSS was 62%

et al. 1897

paranasal sinuses

1. Combined modality therapy with CNS prophylaxis improves outcome compared with RT alone 2. 5-year OS was 29% (Continues)

1. Clinical response 2. OS

Hausdorff et al. 1838

1997 4

Retrospective case series

16 consecutive patients with paranasal sinus lymphoma treated with chemotherapy andRT